Genetic ALS: Discussing a difficult diagnosis

Perspective from Robert Bucelli, MD, PhD Dr. Robert Bucelli is a professor and neurologist at Washington University in St. Louis. He consults and cares for many people with ALS at the school’s world-renowned ALS Center. Dr. Bucelli is a paid consultant for Biogen and was compensated for this article.

Glycogen, an inflammatory sugar molecule produced by certain gut bacteria, may play a key role in driving amyotrophic lateral sclerosis (ALS), a study found. Treatments to degrade glycogen reduced inflammation and extended survival in an animal model of the disease, and clinical trials to test this approach in people…

Last night, I had a dream in which my husband, Todd, did not have ALS. It was a bit of sweet respite from my day-to-day life, and I woke up missing that old version of us. In real life, I am Todd’s caregiver. He is completely paralyzed and needs…

ALS ONE, a Massachusetts-based nonprofit focused on accelerating research into amyotrophic lateral sclerosis (ALS), will soon become part of the ALS Network, an ALS advocacy organization that serves people with ALS in California and Hawaii. “This moment marks a real inflection point for the ALS community,” Sheri…

In the 40-plus years rollators have been around, few design modifications have been made. The changes that have been made target an older demographic. But today’s rollator users don’t just live in nursing homes — we are traveling, attending social events, and seeking designs that match our lifestyles. If you…

Elite athletes, military veterans, first responders, and other high performers have a significantly higher risk of developing amyotrophic lateral sclerosis (ALS) than the general population, and a new study aims to find out why. The initiative, Champion Insights, is seeking up to…

The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy being developed by VectorY Therapeutics for amyotrophic lateral sclerosis (ALS). The open-label PIONEER-ALS (NCT07287397) is enrolling up to 12 adults with ALS at sites in the U.S. and Europe. They will…

Origami Therapeutics is collaborating with Ipsen to develop experimental therapies designed to remove or correct abnormal proteins that build up in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The partnership will focus on small molecules known as protein degraders and correctors. These compounds are designed to…

Coya Therapeutics has raised about $11.1 million in a private investment round to support commercial-readiness efforts for COYA 302, its experimental immune-modulating therapy being developed for amyotrophic lateral sclerosis (ALS). The funding was secured through the sale of more than 2.5 million company shares to two investors, the company…

A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, a bill that aims to improve access to quality medical care for people with amyotrophic lateral sclerosis (ALS). The legislation was introduced in the House by Republican Brian Fitzpatrick of Pennsylvania and Democrats Jason Crow…